scholarly journals Two Cases of Strangulated Ileus with Chylous Ascites after Gastrectomy for Gastric Cancer

2017 ◽  
Vol 78 (11) ◽  
pp. 2454-2459
Author(s):  
Yasuhiro SHIMIZU ◽  
Mitsutaka SUGITA ◽  
Masayuki NAKASHIMA ◽  
Hidetaka ONO ◽  
Hiroyuki BABA
2011 ◽  
Vol 72 (8) ◽  
pp. 2056-2060 ◽  
Author(s):  
Kuniyuki KATO ◽  
Koki OTSUKA ◽  
Tetsuya ITABASHI ◽  
Masanori HAKOZAKI ◽  
Shingo MITOMO ◽  
...  

Author(s):  
Yoshitaka UJI ◽  
Miki TOKUNAGA ◽  
Koji SHINGAMI ◽  
Masaki YAMAGUCHI ◽  
Takashi TAKAO

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 84-84 ◽  
Author(s):  
Tsunehiro Takahashi ◽  
Yoshiro Saikawa ◽  
Norihito Wada ◽  
Hirofumi Kawakubo ◽  
Hiroya Takeuchi ◽  
...  

84 Background: The prognosis for advanced gastric cancer remains poor because of a high rate of metastasis or recurrence. Therefore, treatment options that might improve the prognosis are needed. Radiation is expected to improve the rate of curable resection and local recurrence. To that end, neoadjuvant chemoradiotherapy with S-1 and cisplatin (CDDP) was investigated. Methods: Advanced gastric cancer patients with regional lymph nodes metastases enrolled in this study. The chemoradiotherapy consisted of S-1 on days 1–14 and CDDP on days 1 and 15. The dose range of CDDP in the study was 15 mg/m2 to 30 mg/m2. Radiation therapy was started concurrently with chemotherapy and repeated daily on days 1–5, 8–12, 15–19, and 22–26. After the initial chemoradiation therapy, the chemotherapy was repeated within 2 weeks after the termination of radiotherapy. Surgery was scheduled to take place within 6 weeks after completion of the second cycle of chemotherapy. Results: A total of 9 patients were recruited. There was no dose-limiting toxicity (DLT) in patients both 15 mg/m2 and 20 mg/m2. In the next three patients at 25 mg/m2, there were two cases with DLTs. Therefore, the recommended dose (RD) of CDDP was 20 mg/m2. Eight patients underwent surgery and all had an R0 resection. Postoperative complications occurred in two cases (pancreatic fistula and chylous ascites). However, there was no treatment-related death. The grades of histological therapeutic effect were Grade 1a in two patients, Grade 1b in one patient and Grade 2 in four patients. One patient had no viable cancer cells, which is classified as a Grade 3 histological therapeutic effect and represented a pathological CR. Conclusions: The recommended dose of CDDP is 20mg/m2 bi-weekly and its safety and feasibility as a preoperative therapy are supported in this study. Neoadjuvant chemoradiotherapy can provide remarkable shrinkage of tumors and increases in curability rate would be expected. Further clinical trials in a larger number of patients are recommended to evaluate the validation of neoadjuvant chemoradiotherapy with S-1 and CDDP as a standard treatment strategy for resectable advanced gastric cancer. Clinical trial information: UMIN000008941.


2002 ◽  
Vol 2 (1) ◽  
pp. 20 ◽  
Author(s):  
Jeong Hun Hong ◽  
Byung Wook Min ◽  
Gyung Bum Lee ◽  
Young Jae Mok

Author(s):  
Hideyuki Yokokawa ◽  
Takao Katsube ◽  
Miki Miyazawa ◽  
Ryohei Nishiguchi ◽  
Shinichi Asaka ◽  
...  

AbstractA 61-year-old woman underwent laparoscopy-assisted distal gastrectomy (LADG) with extragastric lymph node dissection (D2). Two months later, she was readmitted to hospital to be treated for chylous ascites. Oral intake was discontinued and total parenteral nutrition started, but increasing body weight and decreasing serum albumin concentration was not controllable. Percutaneous transabdominal thoracic duct embolization (PTTDE) was performed on the 8th day after the readmission. Five days after PTTDE, oral intake was resumed. Seventeen days after PTTDE, the patient was discharged without recurrence of ascites. She has remained asymptomatic. We describe here the first patient with chylous ascites two months after LADG with D2 dissection for early gastric cancer who was successfully treated by PTTDE.


Author(s):  
Hüseyin Çiyiltepe ◽  
Kamuran Cumhur Değer ◽  
Ebubekir Gündeş ◽  
Durmuş Ali Çetin ◽  
Ulaş Aday

2013 ◽  
Vol 74 (5) ◽  
pp. 1281-1285 ◽  
Author(s):  
Hidetaka SHIMA ◽  
Hiroaki SUGIURA ◽  
Yasuhiro SIMIZU ◽  
Kentaro SEKIZAWA ◽  
Kunio KAMEDA ◽  
...  

In Vivo ◽  
2020 ◽  
Vol 34 (2) ◽  
pp. 583-585 ◽  
Author(s):  
SATOSHI TOYOTA ◽  
HIROYUKI ORITA ◽  
YASURO FUKUYAMA ◽  
SAKI MOTOYOSHI ◽  
SHOGO KAWANAMI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document